Carcinoma, Hepatocellular Clinical Trial
Official title:
Phase II Testing of ADI-PEG in Hepatocellular Carcinoma
Amino acid deprivation therapy is an effective means for the treatment of some forms of
cancer. Recently it has been found that human hepatocellular carcinomas (HCC) cell lines
appear to require arginine for growth. Arginine is not an essential amino acid for human
adults or infants as it can be synthesized from citrulline (for review see Rogers 1994).
Therefore, selective elimination of arginine from the circulation may be a means of treating
patients with metastatic melanoma or non resectable HCC.
The enzyme arginine deiminase (ADI) metabolizes arginine into citrulline (Cunin 1986).
However, ADI is only found in microbes and not in humans. ADI is therefore, highly
immunogenic and has a short serum half-life following injection. These potential drawbacks
(microbial source and thus viewed as foreign by the human immune system, and a short serum
half-life) can be overcome by covalent attachment of polyethylene glycol (PEG) to
argininedeiminase and termed this drug ADI-PEG 20.
ADI-PEG 20 appears to be an effective anti-cancer treatment for human HCC. Pharmacokinetic
and pharmacodynamic data indicates a once a week injection of 160 IU/m2 of ADI-PEG 20
eliminates all detectable arginine from the circulation for at least 7 days. This treatment
appears to be well tolerated. The purpose of this study is to determine the efficacy of this
treatment in patients with HCC. Efficacy is a primary end point of this study. No patients
will recieve placebo.
Status | Completed |
Enrollment | 34 |
Est. completion date | October 2003 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
- Histologically confirmed diagnosis of hepatocellular carcinoma. - Non-resectable disease. - Progressive disease after chemotherapy, radiotherapy, surgery or immuno-therapy, and be no longer responding to such therapy, or have refused such therapy. - Been off previous treatment for at least 4 weeks. - Been fully recovered from all prior surgery. - Age of > 18 years. - Karnofsky performance status of > 70. - Expected survival of > 12 weeks. - Total bilirubin < 3.0 mg/dl. - Serum albumin > 3.0 g/dl. - Serum SGOT < 5 x upper limit of normal. - Serum alkaline phosphatase < 5 x upper limit of normal. - Serum ammonia < 55 mg/dl. - Serum glucose > 60 mg/dl. - Serum amylase < 1.5 x upper limit of normal. - ANC > 1,500 / ml. - Platelets > 100,000 / ml. - Female subjects of childbearing age and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study. Subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study. Females must not be pregnant at the start of the study, and a serum HCG pregnancy test must be negative before entry into the study. - Informed consent. - Not be enrolled in other IND studies. - Disease must be measurable or evaluable. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | MD Anderson Cancer center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
FDA Office of Orphan Products Development |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03289533 -
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
|
Phase 1 | |
Terminated |
NCT01141478 -
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
|
N/A | |
Recruiting |
NCT05580835 -
PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
Active, not recruiting |
NCT05389527 -
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04560751 -
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
|
||
Withdrawn |
NCT02939807 -
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT01915602 -
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Completed |
NCT04970212 -
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
|
||
Recruiting |
NCT02403544 -
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
|
Phase 1 | |
Completed |
NCT01897038 -
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Terminated |
NCT01337492 -
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
|
Phase 0 | |
Completed |
NCT01003015 -
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT00559455 -
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT00384800 -
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Terminated |
NCT00582400 -
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
|
Phase 2 | |
Completed |
NCT02859324 -
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
|
Phase 1/Phase 2 | |
Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
Completed |
NCT01915589 -
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 |